Targeted drug development for arthritis

Future Medicinal Chemistry

Volumn 4, Issue 6, 2012, Pages 701-703

  Malemud, Charles J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytokines; disease modifying anti rheumatic biologic drugs; JAK STAT signaling; osteoarthritis; rheumatoid arthritis; SAPK MAPK signaling

Indexed keywords

ADIPOCYTOKINE; CYCLOOXYGENASE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLATELET DERIVED GROWTH FACTOR; TALMAPIMOD; TOFACITINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VX 509;

AGING; CARTILAGE CELL; CHRONIC PAIN; COMPETITIVE INHIBITION; DISEASE COURSE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESEARCH; ENZYME ACTIVITY; HUMAN; OSTEOARTHRITIS; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOARTHRITIS; SIGNAL TRANSDUCTION;

EID: 84860242496     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.24     Document Type: Review

References (20)

1. Livshits G, Zhai G, Hart DJ et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford study. Arthritis Rheum. 60(7), 2037-2045 (2009).
2. El Mabrouk M, Sylvester J, Zafarullah M. Signaling pathways in oncostatin-M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim. Biophys. Acta 1773(3), 309-320 (2007).
3. Fan Z, Bau B, Yang H et al. IL-1b induction of IL-6 and LIF in normal human chondrocytes involves ERK, p38 and NF-kB signaling pathways. Cytokine 28(1), 17-24 (2004).
4. Van Roon JA, Lefeber FP. Role of interleukin-7 in degenerative and inflammatory joint diseases. Arthritis Res. Ther. 10(2), 107 (2008).
5. John T, Kohl B, Mobasheri A et al. Interleukin-18 induces apoptosis in human articular chondrocytes. Histol. Histopathol. 22(5), 469-482 (2007).
6. Rollín R, Alvarez-Lafuente R, Marco F et al. Abnormal transforming growth factor-b expression in mesenchymal stem cells from patients with osteoarthritis. J. Rheumatol. 35(5), 904-906 (2008).
7. Schmidt MB, Chen EH, Lynch SE. A review of the effects of insulin-like growth factor and platelet-derived growth factor on in vivo cartilage healing and repair. Osteoarthritis Cartilage 14(5), 403-412 (2006).
8. Chia SL, Sawaji Y, Burleigh A et al. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheum. 60(7), 2019-2027 (2009).
9. Daheshia M, Yao JQ. The interleukin 1b pathway in the pathogenesis of osteoarthritis. J. Rheumatol. 35(12), 2306-2312 (2008).
10. Glasson SS. In vivo osteoarthritis target validation using genetically-modifed mice. Curr. Drug Targets 8(2), 367-376 (2007).
11. Chevalier X, Goupille P, Beaulieu AD et al. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind placebo-controlled trial. Arthritis Rheum. 61(3), 344-352 (2009)
12. Genovese MC, Cohen SB, Wofsy D et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J. Rheumatol. 38(5), 846-854 (2011).
13. Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin. Arthritis Rheum. 35(1), 24-34 (2005).
14. Malemud CJ, Schulte ME. Is there a final common pathway for arthritis? Future Rheumatol. 3(3), 253-268, (2008).
15. Lane NE, Schnitzer TJ, Birbara CA et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363(16), 1521-1531 (2010).
16. Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum. 56(2), 409-424 (2007).
17. Wisler BA, Dennis JE, Malemud CJ. New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders. Curr. Signal Transduct. Ther. 6(2), 279-291 (2011).
18. Malemud CJ. Gene therapy outcomes in experimental models of inflammatory arthritis. In: Gene Therapy Applications. Kang C (Ed.). InTech Publishing, Vienna, Austria 189-200 (2011).
19. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,500 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009).
20. Vertex Pharmaceuticals. Press release: Phase 2 data for selective oral JAK3 inhibitor VX-509 show significant improvements in signs and symptoms of rheumatoid arthritis. EvaluatePharma, 5 November (2011).